{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:59:58Z","timestamp":1792641598972,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073217"],"award-info":[{"award-number":["82073217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Serine arginine-rich splicing factor 1 (SRSF1) is a key oncogenic splicing factor in various cancers, promoting abnormal gene expression through post-translational regulation. Although the protumoral function of SRSF1 is well-established, the effects of inhibiting tumor-intrinsic SRSF1 on the tumor microenvironment and its impact on CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell-mediated antitumor immunity remain unclear. Our findings indicate that depleting SRSF1 in CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells improve antitumor immune function, glycolytic metabolism, and the efficacy of adoptive T cell therapy. The inactivation of SRSF1 in tumor cells reduces transcription factors, including c-Jun, c-myc, and JunB, facilitating glycolytic metabolism reprogramming, which restores CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell function and inhibits tumor growth. The small-molecule inhibitor TN2008 targets SRSF1, boosting antitumor immune responses and improving immunotherapy effectiveness in mouse models. We therefore introduce a paradigm targeting SRSF1 that simultaneously disrupts tumor cell metabolism and enhances the antitumor immunity of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells.\n                  <\/jats:p>","DOI":"10.1038\/s41392-024-02118-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:04:42Z","timestamp":1737482682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-6923","authenticated-orcid":false,"given":"Gui-Qi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Hao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Liang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Feng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Fu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-1117","authenticated-orcid":false,"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-9201","authenticated-orcid":false,"given":"Zhi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-629X","authenticated-orcid":false,"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Herv\u00e1s-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2118_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","volume":"18","author":"B Ruf","year":"2021","unstructured":"Ruf, B., Heinrich, B. & Greten, T. F. Immunobiology and immunotherapy of HCC: Spotlight on innate and innate-like immune cells. Cell Mol. Immunol. 18, 112\u2013127 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2118_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.semcancer.2022.05.004","volume":"86","author":"JJ Meijer","year":"2022","unstructured":"Meijer, J. J. et al. Small cell lung cancer: Novel treatments beyond immunotherapy. Semin Cancer Biol. 86, 376\u2013385 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2118_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2022.04.010","volume":"40","author":"J Delyon","year":"2022","unstructured":"Delyon, J. & Lebbe, C. IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. Cancer Cell 40, 450\u2013451 (2022).","journal-title":"Cancer Cell"},{"key":"2118_CR5","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1056\/NEJMc2202880","volume":"386","author":"M Ozer","year":"2022","unstructured":"Ozer, M. & Sahin, I. Nivolumab in esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 1958\u20131959 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2118_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccell.2022.04.007","volume":"40","author":"L Pala","year":"2022","unstructured":"Pala, L., De Pas, T. & Conforti, F. Boosting anticancer immunotherapy through androgen receptor blockade. Cancer Cell 40, 455\u2013457 (2022).","journal-title":"Cancer Cell"},{"key":"2118_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat. Immunol. 22, 205\u2013215 (2021).","journal-title":"Nat. Immunol."},{"key":"2118_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","volume":"21","author":"YR Yu","year":"2020","unstructured":"Yu, Y. R. et al. Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion. Nat. Immunol. 21, 1540\u20131551 (2020).","journal-title":"Nat. Immunol."},{"key":"2118_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022\u20131033 (2020).","journal-title":"Nat. Immunol."},{"key":"2118_CR10","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/2159-8290.CD-22-1013","volume":"13","author":"L Wan","year":"2023","unstructured":"Wan, L. et al. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov. 13, 1678\u20131695 (2023).","journal-title":"Cancer Discov."},{"key":"2118_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.molcel.2015.09.005","volume":"60","author":"O Anczuk\u00f3w","year":"2015","unstructured":"Anczuk\u00f3w, O. et al. SRSF1-regulated alternative splicing in breast cancer. Mol. Cell 60, 105\u2013117 (2015).","journal-title":"Mol. Cell"},{"key":"2118_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-021-00495-6","volume":"6","author":"Y Lv","year":"2021","unstructured":"Lv, Y. et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct. Target Ther. 6, 108 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2118_CR13","doi-asserted-by":"publisher","first-page":"109339","DOI":"10.1016\/j.celrep.2021.109339","volume":"36","author":"T Katsuyama","year":"2021","unstructured":"Katsuyama, T. & Moulton, V. R. Splicing factor SRSF1 is indispensable for regulatory T cell homeostasis and function. Cell Rep. 36, 109339 (2021).","journal-title":"Cell Rep."},{"key":"2118_CR14","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1074\/jbc.M113.518662","volume":"289","author":"VR Moulton","year":"2014","unstructured":"Moulton, V. R., Gillooly, A. R. & Tsokos, G. C. Ubiquitination regulates expression of the serine\/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells. J. Biol. Chem. 289, 4126\u20134134 (2014).","journal-title":"J. Biol. Chem."},{"key":"2118_CR15","doi-asserted-by":"publisher","first-page":"12490","DOI":"10.1074\/jbc.M109.091660","volume":"285","author":"VR Moulton","year":"2010","unstructured":"Moulton, V. R. & Tsokos, G. C. Alternative splicing factor\/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J. Biol. Chem. 285, 12490\u201312496 (2010).","journal-title":"J. Biol. Chem."},{"key":"2118_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nsmb.2207","volume":"19","author":"O Anczuk\u00f3w","year":"2012","unstructured":"Anczuk\u00f3w, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19, 220\u2013228 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2118_CR17","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1016\/j.celrep.2017.11.091","volume":"21","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. SRSF1 prevents DNA damage and promotes tumorigenesis through regulation of DBF4B Pre-mRNA splicing. Cell Rep. 21, 3406\u20133413 (2017).","journal-title":"Cell Rep."},{"key":"2118_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biocel.2019.06.003","volume":"113","author":"X Zhou","year":"2019","unstructured":"Zhou, X. et al. The RNA-binding protein SRSF1 is a key cell cycle regulator via stabilizing NEAT1 in glioma. Int. J. Biochem. Cell Biol. 113, 75\u201386 (2019).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2118_CR19","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta, M. et al. \u03b2-catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124\u20131141 (2019).","journal-title":"Cancer Discov."},{"key":"2118_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: Opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"2118_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"2118_CR22","doi-asserted-by":"crossref","unstructured":"Carlisle, J. W. et al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother. Cancer 10, e004803 (2022).","DOI":"10.1136\/jitc-2022-004803"},{"key":"2118_CR23","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1007\/s00262-021-02949-w","volume":"70","author":"P Wu","year":"2021","unstructured":"Wu, P. et al. CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer. Cancer Immunol. Immunother. 70, 3603\u20133616 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2118_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","volume":"12","author":"H Chi","year":"2012","unstructured":"Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325\u2013338 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2118_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ni.2005","volume":"12","author":"GM Delgoffe","year":"2011","unstructured":"Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295\u2013303 (2011).","journal-title":"Nat. Immunol."},{"key":"2118_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic, V. et al. Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29\u201339 (1998).","journal-title":"Cell"},{"key":"2118_CR27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cmet.2021.04.006","volume":"33","author":"YX Ji","year":"2021","unstructured":"Ji, Y. X. et al. A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. Cell Metab. 33, 1171\u20131186.e1179 (2021).","journal-title":"Cell Metab."},{"key":"2118_CR28","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1002\/eji.1830261135","volume":"26","author":"MJ Wick","year":"1996","unstructured":"Wick, M. J. & Pfeifer, J. D. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur. J. Immunol. 26, 2790\u20132799 (1996).","journal-title":"Eur. J. Immunol."},{"key":"2118_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657\u2013671 (2016).","journal-title":"Cell Metab."},{"key":"2118_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"T Cascone","year":"2018","unstructured":"Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 27, 977\u2013987.e974 (2018).","journal-title":"Cell Metab."},{"key":"2118_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"2118_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 33, 1221\u20131233.e1211 (2021).","journal-title":"Cell Metab."},{"key":"2118_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","volume":"29","author":"K Renner","year":"2019","unstructured":"Renner, K. et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 29, 135\u2013150.e139 (2019).","journal-title":"Cell Rep."},{"key":"2118_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep45705","volume":"7","author":"Y Hou","year":"2017","unstructured":"Hou, Y. et al. Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the TLR4\/NF-\u03baB signaling pathways. Sci. Rep. 7, 45705 (2017).","journal-title":"Sci. Rep."},{"key":"2118_CR35","doi-asserted-by":"publisher","first-page":"e004533","DOI":"10.1136\/jitc-2022-004533","volume":"10","author":"K Pinjusic","year":"2022","unstructured":"Pinjusic, K. et al. Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma. J. Immunother. Cancer 10, e004533 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2118_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cmet.2022.02.003","volume":"34","author":"SH M\u00f8ller","year":"2022","unstructured":"M\u00f8ller, S. H. et al. Metabolic programs tailor T cell immunity in viral infection, cancer, and aging. Cell Metab. 34, 378\u2013395 (2022).","journal-title":"Cell Metab."},{"key":"2118_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41590-021-01090-1","volume":"23","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4(+) T cells by preventing ferroptosis. Nat. Immunol. 23, 303\u2013317 (2022).","journal-title":"Nat. Immunol."},{"key":"2118_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41590-018-0311-z","volume":"20","author":"S Gautam","year":"2019","unstructured":"Gautam, S. et al. The transcription factor c-Myb regulates CD8(+) T cell stemness and antitumor immunity. Nat. Immunol. 20, 337\u2013349 (2019).","journal-title":"Nat. Immunol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02118-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02118-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:04:45Z","timestamp":1737482685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02118-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02118-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}